Gabay Avraham — SEC insider filings
SEC reporting owner CIK 1777328. 13 insider filings on record with FilingPulse; latest filed 2026-11-13.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2021-02-08 to 2026-11-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 93,360 shares, $420,944 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 73,360 shares @ $4.51 ($330,744) in ORAMED PHARMACEUTICALS INC., filed 2026-07-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | Chief Financial Officer | 12 | — | 2 legs · 93,360 sh · $420,944 | 15 |
| Lifeward Ltd. (LFWD) | Director | 1 | — | — | 1 |
Insider filings — Gabay Avraham
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Grant/award (A): 357,000 · Grant/award (A): 242,000 | EDGAR |
| 2026-10-02 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Sale (S): 20,000 @ $4.51 | EDGAR |
| 2026-09-25 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Grant/award (A): 209,291 | EDGAR |
| 2026-08-24 | 4 | Lifeward Ltd. (LFWD) | Grant/award (A): 13,643 @ $0 | EDGAR |
| 2026-07-02 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Sale (S): 73,360 @ $4.51 | EDGAR |
| 2026-03-18 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Grant/award (A): 95,889 @ $0 | EDGAR |
| 2026-01-29 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Option exercise (M): 19,000 @ $0 · Option exercise (M): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Grant/award (A): 81,216 @ $0 · Grant/award (A): 115,000 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Grant/award (A): 34,000 @ $0 · Grant/award (A): 42,000 @ $0 | EDGAR |
| 2025-01-06 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Grant/award (A): 188,000 | EDGAR |
| 2024-11-08 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Grant/award (A): 30,000 | EDGAR |
| 2024-06-21 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Grant/award (A): 140,040 | EDGAR |
| 2021-02-08 | 4 | ORAMED PHARMACEUTICALS INC. (ORMP) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1777328 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs